Table 1.
Patient-, disease-, and treatment-related characteristics.
| Characteristics | Locally Advanced Rectal Cancer | Locally Recurrent Rectal Cancer (LRRC, n = 16) |
|---|---|---|
| (LARC, n = 89) | ||
| Initial clinical T-category (n/N [%]) | ||
| T2/rT2 | 6/89 (7) | 1/16 (6) |
| T3/rT3 | 63/89 (71) | 7/16 (44) |
| T4/rT4 | 19/89 (21) | 8/16 (50) |
| n.a. | 1/89 (1) | - |
| Initial clinical N-category (n/N [%]) | ||
| N0/rN0 | 6/89 (7) | 11/16 (69) |
| N1/rN0 | 46/89 (52) | 2/16 (12) |
| N2/rN2 | 36/89 (40) | 3/16 (19) |
| n.a. | 1/89 (1) | - |
| Initial M-category (n/N [%]) | ||
| M0 | 84/89 (94) | 11/16 (69) |
| M1 | 4/89 (5) | 5/16 (31) |
| n.a. | 1/89 (1) | - |
| Previous oncological treatments (n/N [%]) | ||
| surgery | 1/89 (1) | 15/16 (94) |
| radiotherapy | - | 10/16 (63) |
| chemotherapy | - | 12/16 (75) |
| External beam radiotherapy | ||
| median total dose [Gy] | 50.4 (45.0–50.4) | 45.0 (45.0–50.4) |
| median single dose [Gy] | 1.80 (-) | 1.80 (-) |
| radiotherapy delay (n/N [%]) * | 5/88 (6) | 3/16 (19) |
| median duration [days] | 2 (2–6) | 1 (-) |
| total dose reduction (n/N [%]) * | 1/88 (1) | - |
| premature termination * | 1/89 (1) | - |
| Chemotherapy (n/N [%]) | ||
| schedule | ||
| 5-FU and oxaliplatin | 81/89 (91) | 12/16 (75) |
| capecitabine and oxaliplatin | 7/89 (8) | 3/16 (19) |
| 5-FU/capecitabine and oxaliplatin | 1/89 (1) | 1/16 (6) |
| 5-FU protocol adherence | ||
| administered per protocol | 56/81 (69) | 11/12 (92) |
| interval prolongation * | 14/81 (17) | 1/12 (8) |
| dose reduction * | 11/81 (14) | 1/12 (8) |
| premature termination * | 2/81 (2) | - |
| n.a. | 2/81 (2) | - |
| capecitabine protocol adherence | ||
| administered per protocol | 3/7 (43) | 2/3 (67) |
| interval prolongation * | 3/7 (43) | 1/3 (33) |
| dose reduction * | 3/7 (43) | 1/3 (33) |
| premature termination * | 3/7 (43) | - |
| oxaliplatin protocol adherence | ||
| administered per protocol | 58/89 (87) | 13/16 (81) |
| interval prolongation* | 17/89 (19) | 2/16 (13) |
| dose reduction * | 9/89 (10) | 1/16 (6) |
| premature termination * | 6/89 (7) | 1/16 (6) |
| n.a. | 2/89 (2) | - |
| Regional hyperthermia (RHT) | ||
| median number of fractions [n] | 10 (1–11) | 10 (4–10) |
| ≥7 fractions (n/N [%]) | 80/88 (91) | 14/16 (88) |
| mean total treatment time [min] | 837 ± 142 | 831 ± 170 |
| mean CEM43 °C [min] | 6.4 ± 5.2 | ±4.9 |
LARC: locally advanced rectal cancer, LRRC: locally recurrent rectal cancer. 5-FU: 5-fluorouracil; *: multiple responses possible; n.a.: data not available; CEM43 °C: cumulative equivalent minutes at 43 degree Celsius. RHT: regional hyperthermia.